{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-286212","form_type":"8-K","ticker":"AMLX","cik":"0001658551","company_name":"Amylyx Pharmaceuticals, Inc.","filed_at":"2024-12-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.132053+00:00","generated_at":"2026-05-28T22:45:48.047728+00:00","sec_items":["7.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Amylyx and Gubra collaborate on GLP-1 antagonist; milestones up to >$50M","bullets":["Collaboration with Gubra to develop a novel long-acting GLP-1 receptor antagonist; Amylyx to make small upfront and research payments (not material).","Gubra eligible for >$50M in success-based development and commercialization milestones plus mid-single digit royalties.","Amylyx expects cash runway into 2026; upfront and research payments not material to the company.","Screening to identify lead development candidate for IND-enabling studies; Amylyx has option to lead development."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-286212","json":"https://secwatch.observer/filing/0001193125-24-286212.json","markdown":"https://secwatch.observer/filing/0001193125-24-286212.md","text":"https://secwatch.observer/filing/0001193125-24-286212.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1658551/000119312524286212/0001193125-24-286212-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1658551/000119312524286212/d920512d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T22:45:48.047728+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}